Safety and Pharmacokinetics of UV-4B Solution Administered Orally as Multiple Ascending Doses to Healthy Subjects

Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Determine the Safety, Tolerability and Pharmacokinetics of UV-4B Solution Administered Orally in Healthy Subjects

The purpose of this study is to evaluate the safety and pharmacokinetics of UV-4B oral solution when administered to healthy subjects three times a day (TID) for 7 days.

Study Overview

• Status: Terminated
• Conditions: Viral Infection
• Intervention / Treatment: Drug: UV-4B 30 mg oral solution; Drug: Placebo; Drug: UV-4B 75 mg oral solution; Drug: UV-4B 150 mg oral solution; Drug: UV-4B X mg (dose to be determined) oral solution; Drug: UV-4B Y mg (dose to be determined) oral solution

Detailed Description

This is a phase 1, randomized, double-blind, placebo-controlled multiple-ascending dose study to evaluate the safety and pharmacokinetics of UV-4B oral solution when administered to healthy subjects TID for 7 days. Three cohorts of 8 subjects each (6 active, 2 placebo) are planned and up to 2 additional cohorts may be added pending safety review of the initial cohorts. Safety review will occur after each cohort. Safety is evaluated through Day 15 on the basis of adverse event (AE) monitoring, clinical laboratory testing (hematology, serum chemistry, coagulation, urinalysis), vital signs, physical examinations (PE), electrocardiograms (ECG), and fecal occult blood testing. Blood samples are collected at specified intervals up to Day 10 for pharmacokinetic assessment.

• Study Type: Interventional
• Enrollment (Actual): 7
• Phase: Phase 1

Contacts and Locations

Study Locations

• United States
  • Texas
    • Dallas, Texas, United States, 75247
      • Clinical Research Unit
  • Wisconsin
    • Madison, Wisconsin, United States, 53704
      • Clinical Research Unit

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 45 years (Adult)
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• Nonsmoking, healthy male or female subject aged 18 to 45 years, inclusive.
• Female subject is not pregnant and not lactating.
• (Female subjects only who are not postmenopausal or sterile) agreement to use hormonal contraception OR intrauterine device PLUS barrier contraception (condom or occlusive cap such as a diaphragm or surgical vault cap) AND spermicidal foam/gel/cream/suppository starting at least 14 days before the first dose and continuing for at least 3 months after the last dose.
• (Male subjects only) agreement to use barrier contraception during sexual intercourse and to also refrain from sperm donation from the first day of dosing until 3 months after the last dose of the study product.
• Body weight within 60 to 90 kg, inclusive, and body mass index between 18 to 32 kg/m², inclusive.
• Agreement to avoid strenuous exercise starting 4 days before the start of dosing through the period of confinement in the clinical unit and for at least 96 hours before the follow-up visits.

Exclusion Criteria:

• History of allergy to drugs in the iminosugar class.
• Treatment with any investigational products or therapies within 30 days (or 5 half-lives, whichever is greater) before the first day of dosing.
• Current or past history of disease/dysfunction of the pulmonary, cardiovascular, endocrine, hematologic, neurological, immune, gastrointestinal genitourinary, or other body system.
• Abnormalities on physical examination suggestive of conditions that may pose an increased risk to the subject; abnormal electrocardiogram results (excluding benign conditions); and Grade 1 or higher abnormalities in vital signs at screening and Grade 2 or higher abnormalities in vital signs at check-in based on a modified version of the FDA Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials.
• Clinical laboratory tests outside the normal range at screening and Grade 2 or higher at check-in to the clinical unit.
• Creatinine clearance < 90 mL/min (based on Cockcroft-Gault equation).
• Proteinuria greater than or equal to 1+.
• Any known or expected risk of bleeding.
• Scheduled surgical procedure during study participation.
• History of alcohol and/or drug abuse within 1 year prior to dosing and/or a positive urine drug screen for substances of abuse at screening or check-in. Urine alcohol above 50 mg/dL.
• Plasma or blood donation within 30 days before the first day of dosing or intention to donate within 30 days after the final day of dosing.
• Treatment with any medication, either prescription or nonprescription, including dietary supplements or herbal medications, within 14 days before dosing (within 30 days before dosing for hepatic or renal clearance-altering agents) and is unable to refrain from any medication during the study period. Exceptions are acetaminophen (not more than 2 g/day), vitamin products at recommended daily doses or hormonal birth control.
• Positive serology test for HIV antibodies, hepatitis B surface antigen, or hepatitis C virus antibody at screening.
• History of relevant food allergies (ie, eggs or other components of standard clinic meals) or unwilling to comply with diet restrictions.
• Psychological and/or emotional problems which would render the informed consent invalid, or limit the ability of the subject to comply with the study requirements;
• Concurrent enrollment in any other clinical trial within 30 days.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

5

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Cohort 1 - 30 mg; Subjects receiving UV-4B 30 mg oral solution or placebo	Drug: UV-4B 30 mg oral solution; UV-4B 30 mg oral solution administered TID (every 8 ± 0.5 hours) for 7 days; Drug: Placebo; Placebo oral solution administered TID (every 8 ± 0.5 hours) for 7 days
Experimental: Cohort 2 - 75 mg; Subjects receiving UV-4B 75 mg oral solution or placebo	Drug: Placebo; Placebo oral solution administered TID (every 8 ± 0.5 hours) for 7 days; Drug: UV-4B 75 mg oral solution; UV-4B 75 mg oral solution administered TID (every 8 ± 0.5 hours) for 7 days
Experimental: Cohort 3 - 150 mg; Subjects receiving UV-4B 150 mg oral solution or placebo	Drug: Placebo; Placebo oral solution administered TID (every 8 ± 0.5 hours) for 7 days; Drug: UV-4B 150 mg oral solution; UV-4B 150 mg oral solution administered TID (every 8 ± 0.5 hours) for 7 days
Experimental: Cohort 4 - X mg (dose to be determined); Subjects receiving UV-4B X mg (dose to be determined) oral solution or placebo	Drug: Placebo; Placebo oral solution administered TID (every 8 ± 0.5 hours) for 7 days; Drug: UV-4B X mg (dose to be determined) oral solution; UV-4B X mg (dose to be determined) oral solution administered TID (every 8 ± 0.5 hours) for 7 days
Experimental: Cohort 5 - Y mg (dose to be determined); Subjects receiving UV-4B Y mg (dose to be determined) oral solution or placebo	Drug: Placebo; Placebo oral solution administered TID (every 8 ± 0.5 hours) for 7 days; Drug: UV-4B Y mg (dose to be determined) oral solution; UV-4B Y mg (dose to be determined) oral solution administered TID (every 8 ± 0.5 hours) for 7 days

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Subjects Reporting Treatment-emergent Adverse Events (TEAEs) by Group	The incidence of TEAEs spontaneously reported by subjects or elicited during examination is reported by dose group. Subjects having multiple TEAEs are counted only once.	From the time of first dosing on Day 1 through the Day 15 final follow-up visit
Number of Subjects Reporting Serious Adverse Events (SAEs) by Group	The incidence of SAEs spontaneously reported by subjects or elicited during examination is reported by dose group. Subjects having multiple SAEs are counted only once.	From the time of first dosing on Day 1 through the Day 15 final follow-up visit
Number of Subjects With Clinical Laboratory Abnormalities of Toxicity Grade 1 or Higher by Group	Clinical laboratory abnormalities are presented as the total of Grade 1 (mild) through Grade 4 (potentially life-threatening) abnormalities according to criteria adapted from the Food and Drug Administration (FDA) Guidance for Industry, Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials (September 2007) and the Division of Microbiology and Infectious Diseases (DMID) Adult Toxicity Table (November 2007). Within each parameter, subjects having multiple abnormalities are counted only once.	From the time of first dosing on Day 1 through the Day 15 final follow-up visit

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Subjects With Outlying Vital Sign Results by Group	Vital signs of blood pressure (BP), pulse, respiratory rate, and oral temperature were taken after being supine for 10 minutes. Orthostatic vital signs (BP, pulse) were taken after 2 minutes standing. Vital sign results are presented as the number of subjects having Grade 1 (mild) through Grade 4 (potentially life-threatening) abnormalities according to criteria adapted from the FDA Guidance for Industry, Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials (September 2007), or having abnormal orthostatic change (standing minus supine result). Within each parameter, subjects having multiple abnormalities are counted only once.	From the time of first dosing on Day 1 through the Day 15 final follow-up visit
Number of Subjects With 12-lead Electrocardiogram (ECG) Abnormalities Postdose by Group	ECGs (ventricular heart rate, wave intervals - PR, QRS, QT, QTcF) were recorded in a supine position (for at least 10 minutes). Baseline was calculated from the average of the triplicate ECGs on Day 1 predose. Within each parameter, subjects having multiple abnormalities are counted only once.	From the time of first dosing on Day 1 through the Day 15 final follow-up visit
Maximum Plasma Concentration (Cmax)	Plasma concentrations of UV-4 are determined by means of high performance liquid chromatography/tandem mass spectrometric assay. Values of Cmax are derived from individual subject plasma concentration-time data. Blood collected at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 5, 6, and 8 hrs after the first dose on Day 1; and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 5, 6, 8, 10, 12, and 14 hrs after the final dose on Day 7.	Day 1, Day 7
Time of Maximum Plasma Concentration (Tmax)	Plasma concentrations of UV-4 are determined by means of high performance liquid chromatography/tandem mass spectrometric assay. Values of tmax are derived from individual subject plasma concentration-time data. Blood collected at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 5, 6, and 8 hrs after the first dose on Day 1; and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 5, 6, 8, 10, 12, and 14 hrs after the final dose on Day 7.	Day 1, Day 7
Area Under the Concentration-time Curve From Time Zero (Predose) to Time of the Last Quantifiable Concentration After the Last Dose [AUC(0-last)]	Plasma concentrations of UV-4 are determined by means of high performance liquid chromatography/tandem mass spectrometric assay. Values of AUC(0-last) are derived from individual subject plasma concentration-time data, calculated using the linear trapezoidal rule for increasing concentrations and the logarithmic rule for decreasing concentrations. Blood collected at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 5, 6, 8, 10, 12, and 14 hrs after the final dose on Day 7.	Day 7
Total Daily Exposure at Steady State: Area Under the Concentration-time Curve From Time Zero (Predose) Until 24 Hours After the Last Dose [AUC(0-24)]	Plasma concentrations of UV-4 are determined by means of high performance liquid chromatography/tandem mass spectrometric assay. Values of AUC(0-24) are derived from individual subject plasma concentration-time data, calculated as AUC(0-8) x 3 (Day 7 last dose only). Blood collected at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 5, 6, 8, 10, 12, and 14 hrs after the final dose on Day 7.	Day 7
Area Under the Concentration-time Curve From Time Zero (Predose) Until 8 Hours After the Final Dose [AUC(0-8)]	Plasma concentrations of UV-4 are determined by means of high performance liquid chromatography/tandem mass spectrometric assay. Values of AUC(0-8) are derived from individual subject plasma concentration-time data, calculated using the linear trapezoidal rule for increasing concentrations and the logarithmic rule for decreasing concentrations. Blood collected at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 5, 6, and 8 hrs after the first dose on Day 1; and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 5, 6, 8, 10, 12, and 14 hrs after the final dose on Day 7.	Day 1, Day 7
Apparent Systemic Clearance (CL/F) at Steady State	Plasma concentrations of UV-4 are determined by means of high performance liquid chromatography/tandem mass spectrometric assay. Values of CL/F are derived from individual subject plasma concentration-time data, calculated as dose (free-base equivalent) divided by AUC(0-8). Blood collected at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 5, 6, 8, 10, 12, and 14 hrs after the final dose on Day 7.	Day 7
Apparent Volume of Distribution of UV-4 During the Terminal Phase (Vz/F) After Multiple Doses	Plasma concentrations of UV-4 are determined by means of high performance liquid chromatography/tandem mass spectrometric assay. Values of Vz/F are derived from individual subject plasma concentration-time data, calculated as CL/F divided by λz. Blood collected at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 5, 6, 8, 10, 12, and 14 hrs after the final dose on Day 7.	Day 7
Apparent Terminal Half Life (t1/2)	Plasma concentrations of UV-4 are determined by means of high performance liquid chromatography/tandem mass spectrometric assay. Values of t1/2 are derived from individual subject plasma concentration-time data, calculated as ln2/λz. Blood collected at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 5, 6, 8, 10, 12, and 14 hrs after the final dose on Day 7.	Day 7
Accumulation Ratio (AR)	Accumulation Ratio (AR) Day 1/Day 7	Day 7

Collaborators and Investigators

• Sponsor: Emergent BioSolutions
• Collaborators: National Institute of Allergy and Infectious Diseases (NIAID)
• Investigators: Study Director: Timothy Babinchak, MD, Emergent BioSolutions

Publications and helpful links

Helpful Links

• For information on dengue fever

Study record dates

Study Major Dates

• Study Start (Actual): May 27, 2016
• Primary Completion (Actual): March 2, 2017
• Study Completion (Actual): March 2, 2017

Study Registration Dates

• First Submitted: February 22, 2016
• First Submitted That Met QC Criteria: February 25, 2016
• First Posted (Estimated): March 2, 2016

Study Record Updates

• Last Update Posted (Actual): March 18, 2024
• Last Update Submitted That Met QC Criteria: March 14, 2024
• Last Verified: March 1, 2024

More Information

Terms related to this study

• Keywords: Virus Diseases; Dengue; Pharmacologic Actions; Therapeutic Uses; Arbovirus Infections; Flaviviridae Infections; Flavivirus Infections; Hemorrhagic Fevers, Viral; RNA Virus Infections; Pharmaceutical Solutions
• Additional Relevant MeSH Terms: Infections; Virus Diseases; Pharmaceutical Solutions
• Other Study ID Numbers: DMID 15-0062; HHSN272201100030C (Other Grant/Funding Number: NIAID); 8311-270 (Other Identifier: Covance)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No